This is the authors' abstract. We don't add key points for this paper.
Our data suggest that a longer CIM use in the first 5 years of disease can have negative effects on cognitive outcome in Dravet syndrome. An early diagnosis is essential to avoid these drugs. Furthermore, we identified age at first afebrile seizure as an important predictor for evolution of seizures into Dravet syndrome and for the severity of Dravet syndrome, which can be used to counsel parents of young patients with SCN1A-related seizures.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lange et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: